Literature DB >> 22411347

Breast cancer: Neoadjuvant bevacizumab treatment-signal or noise?

Harold J Burstein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22411347     DOI： 10.1038/nrclinonc.2012.34

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  8 in total

1.  Don't pick the loser: lessons from the GeparQuinto trial.

Authors:  Stephen K Chia
Journal:  Lancet Oncol       Date:  2012-01-17       Impact factor: 41.316

2.  Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions.

Authors:  Alberto Ocaña; Eitan Amir; Francisco Vera; Elizabeth A Eisenhauer; Ian F Tannock
Journal:  J Clin Oncol       Date:  2010-12-13       Impact factor: 44.544

3.  Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.

Authors:  Gunter von Minckwitz; Holger Eidtmann; Mahdi Rezai; Peter A Fasching; Hans Tesch; Holm Eggemann; Iris Schrader; Kornelia Kittel; Claus Hanusch; Rolf Kreienberg; Christine Solbach; Bernd Gerber; Christian Jackisch; Georg Kunz; Jens-Uwe Blohmer; Jens Huober; Maik Hauschild; Tanja Fehm; Berit Maria Müller; Carsten Denkert; Sibylle Loibl; Valentina Nekljudova; Michael Untch
Journal:  N Engl J Med       Date:  2012-01-26       Impact factor: 91.245

4.  Bevacizumab added to neoadjuvant chemotherapy for breast cancer.

Authors:  Harry D Bear; Gong Tang; Priya Rastogi; Charles E Geyer; André Robidoux; James N Atkins; Luis Baez-Diaz; Adam M Brufsky; Rita S Mehta; Louis Fehrenbacher; James A Young; Francis M Senecal; Rakesh Gaur; Richard G Margolese; Paul T Adams; Howard M Gross; Joseph P Costantino; Sandra M Swain; Eleftherios P Mamounas; Norman Wolmark
Journal:  N Engl J Med       Date:  2012-01-26       Impact factor: 91.245

5.  Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials.

Authors:  Gunter von Minckwitz; Michael Untch; Eveline Nüesch; Sibylle Loibl; Manfred Kaufmann; Sherko Kümmel; Peter A Fasching; Wolfgang Eiermann; Jens-Uwe Blohmer; Serban Dan Costa; Keyur Mehta; Jörn Hilfrich; Christian Jackisch; Bernd Gerber; Andreas du Bois; Jens Huober; Claus Hanusch; Gottfried Konecny; Werner Fett; Elmar Stickeler; Nadia Harbeck; Volkmar Müller; Peter Jüni
Journal:  Breast Cancer Res Treat       Date:  2010-11-03       Impact factor: 4.872

6.  Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.

Authors:  H M Kuerer; L A Newman; T L Smith; F C Ames; K K Hunt; K Dhingra; R L Theriault; G Singh; S M Binkley; N Sneige; T A Buchholz; M I Ross; M D McNeese; A U Buzdar; G N Hortobagyi; S E Singletary
Journal:  J Clin Oncol       Date:  1999-02       Impact factor: 44.544

7.  Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

Authors:  Harry D Bear; Stewart Anderson; Roy E Smith; Charles E Geyer; Eleftherios P Mamounas; Bernard Fisher; Ann M Brown; Andre Robidoux; Richard Margolese; Morton S Kahlenberg; Soonmyung Paik; Atilla Soran; D Lawrence Wickerham; Norman Wolmark
Journal:  J Clin Oncol       Date:  2006-04-10       Impact factor: 44.544

Review 8.  Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease.

Authors:  Julie R Gralow; Harold J Burstein; William Wood; Gabriel N Hortobagyi; Luca Gianni; Gunter von Minckwitz; Aman U Buzdar; Ian E Smith; William F Symmans; Baljit Singh; Eric P Winer
Journal:  J Clin Oncol       Date:  2008-02-10       Impact factor: 44.544
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.